In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants - PubMed (original) (raw)
. 2000 May 23;39(20):6136-44.
doi: 10.1021/bi000201f.
Affiliations
- PMID: 10821687
- DOI: 10.1021/bi000201f
In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants
T C Gamblin et al. Biochemistry. 2000.
Abstract
Tau polymerization into the filaments that compose neurofibrillary tangles is seminal to the development of many neurodegenerative diseases. It is therefore important to understand the mechanisms involved in this process. However, a consensus method for monitoring tau polymerization in vitro has been lacking. Here we demonstrate that illuminating tau polymerization reactions with laser light and measuring the increased scattering at 90 degrees to the incident beam with a digital camera results in data that closely approximate the mass of tau polymer formation in vitro. The validity of the technique was demonstrated over a range of tau concentrations and through multiple angle scattering measurements. In addition, laser light scattering data closely correlated with quantitative electron microscopy measurements of the mass of tau filaments. Laser light scattering was then used to measure the efficiency with which the mutant tau proteins found in frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) form filamentous structures. Several of these mutant proteins display enhanced polymerization in the presence of arachidonic acid, suggesting a direct role for these mutations in tau the filament formation that characterizes FTDP-17.
Similar articles
- FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion.
Yen S, Easson C, Nacharaju P, Hutton M, Yen SH. Yen S, et al. FEBS Lett. 1999 Nov 12;461(1-2):91-5. doi: 10.1016/s0014-5793(99)01427-1. FEBS Lett. 1999. PMID: 10561502 - Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.
Nacharaju P, Lewis J, Easson C, Yen S, Hackett J, Hutton M, Yen SH. Nacharaju P, et al. FEBS Lett. 1999 Mar 26;447(2-3):195-9. doi: 10.1016/s0014-5793(99)00294-x. FEBS Lett. 1999. PMID: 10214944 - Molecular genetics of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
Kowalska A. Kowalska A. Folia Neuropathol. 2002;40(3):111-8. Folia Neuropathol. 2002. PMID: 12572916 Review. - Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation.
Maeda S, Sato Y, Takashima A. Maeda S, et al. Neurobiol Aging. 2018 Sep;69:26-32. doi: 10.1016/j.neurobiolaging.2018.04.014. Epub 2018 May 7. Neurobiol Aging. 2018. PMID: 29852407 - Hereditary frontotemporal dementia caused by Tau gene mutations.
van Swieten J, Spillantini MG. van Swieten J, et al. Brain Pathol. 2007 Jan;17(1):63-73. doi: 10.1111/j.1750-3639.2007.00052.x. Brain Pathol. 2007. PMID: 17493040 Free PMC article. Review.
Cited by
- Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties.
Ballatore C, Crowe A, Piscitelli F, James M, Lou K, Rossidivito G, Yao Y, Trojanowski JQ, Lee VM, Brunden KR, Smith AB 3rd. Ballatore C, et al. Bioorg Med Chem. 2012 Jul 15;20(14):4451-61. doi: 10.1016/j.bmc.2012.05.027. Epub 2012 May 23. Bioorg Med Chem. 2012. PMID: 22717239 Free PMC article. - Tau and tauopathies.
Lee G, Leugers CJ. Lee G, et al. Prog Mol Biol Transl Sci. 2012;107:263-93. doi: 10.1016/B978-0-12-385883-2.00004-7. Prog Mol Biol Transl Sci. 2012. PMID: 22482453 Free PMC article. Review. - O-GlcNAc modification differentially regulates microtubule binding and pathological conformations of tau isoforms in vitro.
Alhadidy MM, Stemmer PM, Kanaan NM. Alhadidy MM, et al. J Biol Chem. 2025 Mar;301(3):108263. doi: 10.1016/j.jbc.2025.108263. Epub 2025 Feb 3. J Biol Chem. 2025. PMID: 39909381 Free PMC article. - Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR, Ballatore C, Crowe A, Smith AB 3rd, Lee VM, Trojanowski JQ. Brunden KR, et al. Exp Neurol. 2010 Jun;223(2):304-10. doi: 10.1016/j.expneurol.2009.08.031. Epub 2009 Sep 8. Exp Neurol. 2010. PMID: 19744482 Free PMC article. Review. - Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.
Dawson HN, Cantillana V, Jansen M, Wang H, Vitek MP, Wilcock DM, Lynch JR, Laskowitz DT. Dawson HN, et al. Neuroscience. 2010 Aug 11;169(1):516-31. doi: 10.1016/j.neuroscience.2010.04.037. Epub 2010 Apr 29. Neuroscience. 2010. PMID: 20434528 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical